• Our Company
    • Our Purpose
    • Our Leadership
    • Our Locations
  • Our Focus
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • Our Science
    • Pipeline
    • Relugolix Combination Tablet
    • MVT-602
  • Our Medicines
  • Our Advocacy
    • Forward Together
  • Join The Team
    • Our Culture
    • Our Benefits
    • Open Positions
  • For Media
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • Expanded Access
  • Contact Us
  • Twitter
  • LinkedIn
  • Instagram

Event Details

MYFEMBREE FDA sNDA Approval Conference Call

08 Aug 2022 at 8:30 am ET

Click here for webcast

Supporting Materials

Presentation

Transcript

  • Our Company
    • Our Purpose
    • Our Leadership
    • Our Locations
  • Our Focus
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • Our Science
    • Pipeline
    • Relugolix Combination Tablet
    • MVT-602
  • Our Medicines
  • Our Advocacy
    • Forward Together
  • Join The Team
    • Our Culture
    • Our Benefits
    • Open Positions
  • For Media
    • Press Releases
    • Events
    • Presentations
    • Corporate Governance
    • Expanded Access
  • Contact Us
  • Twitter
  • LinkedIn
  • Instagram
© 2023 Myovant Sciences GmbH. All rights reserved.
Terms of Use Privacy Policy Cookie Policy PV Policy SMS Terms & Conditions Compliance & Prescriber Information
×

This website uses cookies to help us give you the best experience when you visit. By using this website you consent to the use of these cookies. Find out more about how we use cookies and how to manage them by reading our Cookie Policy.